VoiceMed secures €1 million to scale AI-powered respiratory screening
Rome-based healthtech startup VoiceMed has reached a total of €1 million in funding as it launches a new pilot program aimed at the early detection of chronic respiratory diseases. The company is building a non-invasive screening tool that analyzes a person’s voice and breathing sounds to flag potential issues such as asthma, COPD and other chronic respiratory diseases.
Leveraging proprietary AI algorithms and digital biomarkers, VoiceMed aspires to turn any smartphone or connected device into an accessible pre-diagnostic tool. The fresh capital will be used to expand clinical validation, strengthen the startup’s machine learning models and support regulatory and commercial rollout across Europe.
Pilot program targets early detection and remote monitoring
The newly announced pilot focuses on integrating VoiceMed’s technology into remote care pathways for patients at risk of long-term respiratory conditions. Participants will record short voice and breathing samples, which are then processed by cloud-based AI systems to detect subtle patterns associated with inflammation, airway obstruction or reduced lung capacity.
The company positions its solution as a fast, low-cost layer on top of traditional pulmonary function tests. By offering continuous, at-home screening, VoiceMed aims to help clinicians identify deterioration earlier, reduce hospitalizations and support more personalized treatment plans.
Addressing the global burden of respiratory disease
Chronic respiratory illnesses are among the leading causes of death and disability worldwide, placing a heavy burden on healthcare systems. The rise of telemedicine and remote monitoring since the COVID-19 pandemic has accelerated demand for tools that can deliver reliable insights without requiring in-person visits.
With its latest funding milestone and pilot launch, VoiceMed is positioning itself at the intersection of digital health, artificial intelligence and respiratory medicine. If the pilot confirms high sensitivity and specificity, the startup could become a key player in preventative respiratory care, offering clinicians and healthcare providers a scalable way to screen large populations using only a voice sample.